OFE 40,1 IDS- 02/08/2906

PTO/SB/08A (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

4 TRAD Brostitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10,622,302			
Filing Date	July 18, 2003			
First Named Inventor	Stec			
Art Unit	1617			
Examiner Name	D Clayton			
Attorney Docket Number	AI C.2			

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RC		^{US-} 5,504,111	04-02-1996	Flavin et al	entire document
RC		^{US-} 2002/0013331 A1	01-31-2002	Williams et al	entire document
•		US-			
		US-		·	
		US-		1	
		US-			
		US-	<u> </u>	<u> </u>	
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Cite Fore	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T	
		Country Code ³ "Number ⁴ "Kind Code ⁶ (ff known)	MM-DD-YYYY		Or Relevant Figures Appear	۲

Examiner Signature	/Renee Claytor/	Date Considered	12/20/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. 8END TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SBA88 (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete # Known

Application Number. Substitute for form 1449/PTO Filing Date INFORMATION DISCLOSURE July 18, 2003 STATEMENT BY APPLICANT **First Named Inventor**

Stec Art Unit 1617 (Use as many sheets as necessary) **Examiner Name** D. Clayton Attomey Docket Number Sheet 2 ALS-2

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		TAO et al: Cardioprotective effects of thioredoxin in myocardial ischemia Pharmacology. Vol 101. No. 31 p. 11471-11476, Pub: Nat'l Academy of Science, 08-03-2004 Reference not given.	
		Eiznhamer et al: Effective attenuation of endotoxin induced acute lung inlury by 2,3-diacetyloxybenzoic acid, Pulmonary Pharmacology & Therapeutics, Vol. 17 (2004),	
		(cont) p. 105-110, Pub: Elsevier Ltd., 11-26-2003 Reference not given RC	
RC		Ermakova, Influence of sodium salicylate, acetylsalicylate, 2,3-dihydroxybenzoic and 2,3-diacetoxybenzoic acids on the blood coagulation system; Farmakol Toksikol, 1975	
		(cont) 1975; 38:445-9 (Note: only abstract available; no additional information available)	
•			
			

Examiner		Date	
Signature	/Renee Claytor/	Considered	12/20/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.